BIO Investor Forum: Epeius Biotechnologies Investment Opportunity

SAN FRANCISCO, Calif. — Epeius Biotechnologies Corporation (www.epeiusbiotech.com), an emerging leader in the field of targeted genetic medicine, announced today that Frederick L. Hall, President and CEO, and Dr. Erlinda M. Gordon, Medical Director, will be participating in the 8th Annual BIO Investor Forum being held October 28-29, 2009, at the Palace Hotel in San Francisco. Participating companies that are poised for leadership status in areas of therapeutic innovation are chosen through a competitive screening process, with input by an advisory committee comprised of members from top-tier firms focused on investing and banking in the life sciences industry.

The selection of Epeius Biotechnologies as an investment opportunity was based on the accomplishment of significant clinical development milestones with its lead oncology product, Rexin-G, a tumor-targeted anti-cancer agent that is approved for use against all solid tumors by the Philippine FDA, and has recently received both Orphan Drug priorities and Fast Track designation by the U.S. FDA.

Epeius Biotechnologies is among a select group of companies which are recognized as those that are creating real value through development-stage programs with near-term clinical catalysts. According to the top-tier investor forum advisory committee, “These are the companies that will help drive the investment and deal making in the live sciences sector and global innovation in healthcare.”

This prestigious forum provides an opportunity for senior management of Epeius Biotechnologies to showcase the remarkable clinical development of Rexin-G(R), as stand-alone therapy for otherwise intractable metastatic cancers, and to partner with savvy investors that are capable of expediting the development of Rexin-G in the larger global market.

About Epeius Biotechnologies:

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its leading oncology products and its tumor-targeted delivery systems.

To learn more about our pipeline of proprietary biotechnologies currently available for clinical development and/or new product development, please visit us at www.epeiusbiotech.com .

About Tabitha Berg

Tabitha Angel Berg is an aspiring author and musician and joined eNewsChannels in Nov. 2006 as an editor and mistress of the WP-based content management system (CMS). She likes ferrets better than cats and tea better than coffee, and is a devout iPad evangelist. Nobody pays her to like Dr. Pepper, but wouldn't you like to be a pepper, too?

• More Posts (1649)

• WTC Insurance Services LLC adds Jeffrey R. Jamison in New York
• Zen Cart OpenCuro payment module is now available
• Teach English Abroad in South Korea with new book by author Jonathan Goodwin
• World Savvy: Thirty Students Launch Projects to Improve Community and World After Participating in Educational Program
• Celebrating its 10th Anniversary in 2012, World Savvy is a nonprofit organization serving youth and educators nationally
• Edgewood Partners Insurance Center names Stan Sanchez as Principal in San Francisco, Calif.
• Certified Cyber Intel and CounterIntel Analyst Boot Camps announced at RSA Conference by Treadstone 71 LLC
• The Futon Store offers Comprehensive Guide on the Usage of Chemicals in Your Mattress

Comments are closed for this story, sorry. Please provide any feedback to the company(s) mentioned in the above story or press release.